Nuvectis Pharma inc (NVCT) - News Archive

Showing 3 of 3 results.

Nuvectis Pharma Advancements in NSCLC Treatment Amidst Financial Challenges

In a significant stride towards improving the treatment landscape for non-small cell lung cancer (NSCLC), Nuvectis Pharma has announced the publication of a research study conducted at the Lerner Research Institute, par...

Jun 14, 2025 • Major Pharmaceutical Preparations Industry Clinical Study Nuvectis Pharma

Nuvectis Pharma Shows Promise in NSCLC Treatment Despite Revenue Challenges

In a recent announcement, Nuvectis Pharma (NASDAQ: NVCT) reported encouraging findings from a study conducted at the Cleveland Clinic s Lerner Research Institute. The study, published in the peer-reviewed journal Molecu...

Mar 8, 2025 • Major Pharmaceutical Preparations Industry Business Update NASDAQInc Phase Try Now Inc

A Pioneering Advance in Oncological Pharmacology The Granting of Orphan Drug Designation for NXP800

In the evolving landscape of oncological therapeutics, the recent announcement from Nuvectis Pharma, Inc. regarding the Orphan Drug Designation granted by the venerable United States Food and Drug Administration (FDA) m...

Aug 29, 2024 • Major Pharmaceutical Preparations Industry Clinical Study